Literature DB >> 8112380

(+) and (-) terbutaline are sulphated at a higher rate in human intestine than in liver.

G M Pacifici1, M Eligi, L Giuliani.   

Abstract

The sulphation of (+) and (-) terbutaline was investigated in specimens of human intestinal mucosa isolated from the duodenum, ileum, ascending colon and sigmoid colon and in specimens of liver and lung. The lung specimens came from 8 current smokers and 11 ex-smokers, the latter having stopped at least 3 months before surgery. The rates (pmol.min-1.mg protein-1) of (+) and (-) terbutaline sulphation were 1195 and 948 (duodenum), 415 and 317 (ileum), 268 and 166 (ascending colon), 263 and 193 (sigmoid colon) and 45 and 34 (liver), respectively. Terbutaline sulphotransferase was more active in the small and large intestine than in the liver. In the lung, the rate of (+) terbutaline sulphation was 118 (ex-smokers) and 82 (smokers), and for (-) terbutaline it was 82 (ex-smokers) and 56 (smokers). In the gut, the activity of catechol sulphotransferase was significantly correlated with that of (+)- and (-)- terbutaline sulphotransferase whereas no correlation was found with phenol sulphotransferase. This correlation, the finding of the higher activity of terbutaline sulphotransferase in gut than in liver, and the pronounced thermal inactivation of the enzyme, are all consistent with the view that catechol sulphotransferase has a role in the sulphation of terbutaline.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112380     DOI: 10.1007/bf00315522

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Stereoselective sulfate conjugation of 4-hydroxypropranolol and terbutaline by the human liver phenolsulfotransferases.

Authors:  T Walle; U K Walle
Journal:  Drug Metab Dispos       Date:  1992 Mar-Apr       Impact factor: 3.922

2.  Dopamine sulphotransferase is better developed than p-nitrophenol sulphotransferase in the human fetus.

Authors:  M Cappiello; L Giuliani; A Rane; G M Pacifici
Journal:  Dev Pharmacol Ther       Date:  1991

3.  Human liver sulphotransferase and UDP-glucuronosyltransferase: structure-activity relationship for phenolic substrates.

Authors:  A Temellini; M Franchi; L Giuliani; G M Pacifici
Journal:  Xenobiotica       Date:  1991-02       Impact factor: 1.908

4.  Differential distribution of phenol and catechol sulphotransferases in human liver and intestinal mucosa.

Authors:  M Cappiello; L Giuliani; G M Pacifici
Journal:  Pharmacology       Date:  1990       Impact factor: 2.547

5.  Phenol sulfotransferases.

Authors:  R D Sekura; W B Jakoby
Journal:  J Biol Chem       Date:  1979-07-10       Impact factor: 5.157

6.  Sulfotransferase in humans: development and tissue distribution.

Authors:  G M Pacifici; M Franchi; C Colizzi; L Giuliani; A Rane
Journal:  Pharmacology       Date:  1988       Impact factor: 2.547

7.  Cigarette smoke inhibits cytosolic but not microsomal epoxide hydrolase of human lung.

Authors:  S Petruzzelli; M Franchi; L Gronchi; A Janni; F Oesch; G M Pacifici; C Giuntini
Journal:  Hum Exp Toxicol       Date:  1992-03       Impact factor: 2.903

8.  Human and rat liver phenol sulfotransferase: structure-activity relationships for phenolic substrates.

Authors:  N R Campbell; J A Van Loon; R S Sundaram; M M Ames; C Hansch; R Weinshilboum
Journal:  Mol Pharmacol       Date:  1987-12       Impact factor: 4.436

9.  Phenol sulfotransferase in humans: properties, regulation, and function.

Authors:  R M Weinshilboum
Journal:  Fed Proc       Date:  1986-07

Review 10.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

View more
  8 in total

Review 1.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Investigation of distribution and elimination of terbutaline sulfate in the perfused rat liver preparation.

Authors:  Selma Sahin; Yasemin Karabey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

3.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

Review 4.  Human colonocyte detoxification.

Authors:  W E Roediger; W Babidge
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

Review 5.  The pharmacokinetics of levosalbutamol: what are the clinical implications?

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 6.  Enantioselective disposition of albuterol in humans.

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

7.  Interindividual variability in the rate of salbutamol sulphation in the human lung.

Authors:  G M Pacifici; C De Santi; A Mussi; C A Ageletti
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

8.  Influence of vitamin C on the absorption and first pass metabolism of propranolol.

Authors:  J P Gonzalez; A Valdivieso; R Calvo; J M Rodríguez-Sasiaín; R Jimenez; C Aguirre; P du Souich
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.